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Summary
AIMS: We aimed to identify familial hypercholestero-
laemia mutation carriers among participants to the
Lausanne Institutional Biobank (BIL). Our experimental
workflow was designed as a proof-of-concept demonstra-
tion of the resources and services provided by our integ-
rated institutional clinical research support platform.
METHODS: Familial hypercholesterolaemia was used as
a model of a relatively common yet often underdiagnosed
and inadequately treated Mendelian disease. Clinical and
laboratory information was extracted from electronic hos-
pital records. Patients were selected using elevated plasma
cholesterol levels (total cholesterol ≥7.5 mM or low-dens-
ity lipoprotein cholesterol ≥5 mM), premature coronary
artery disease status and age (18–60 yr) as main inclusion
criteria. LDLR, APOB and PCSK9 were analysed by high-
throughput DNA sequencing. The most relevant mutations
were confirmed by Sanger sequencing.
RESULTS: Of 23 737 patients contacted by the BIL,
17 760 individuals consented to participate and 13 094
wished to be recontacted if there were findings requiring
clinical action. Plasma cholesterol records were available
for 5111 participants, of whom 94 were selected for genetic
screening. Twenty-five of the tested patients presented with
premature coronary artery disease while 69 had no such
diagnosis. Seven heterozygous carriers of eight rare coding
missense variants were identified. Three mutations were
pathogenic (APOB p.R3527Q) or likely pathogenic (LDLR
p.C27W, LDLR p.P526S) for hypercholesterolaemia, while
the others were either benign or of unknown significance.
One patient was a double heterozygote for variants APOB
p.R3527Q and LDLR p.P526S.
CONCLUSION: This work illustrates how clinical and
translational research can benefit from a dedicated platform
integrating both a hospital-based biobank and a data sup-
port team.
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Introduction and background
The PSRC, a centralised support hub for translational
research and genomic medicine
In 2013, the Centre Hospitalier Universitaire Vaudois
(CHUV) and the University of Lausanne (UNIL) launched
the Lausanne Institutional Biobank (BIL), a repository of
biological samples and hospital records collected from
CHUV patients. This facility is dedicated to research and,
ultimately, genomic medicine [1]. In 2015, in partnership
with competence centres based in Lausanne, in particular
VITAL-IT, the high performance computing centre of the
Swiss Institute of Bioinformatics (SIB), the Genomic Tech-
nologies Facility (GTF) of UNIL and the information se-
curity ISC-GE laboratory of EPFL, the Institutions further
established an integrated in-house clinical research support
platform, the PSRC. The platform combines expertise cov-
ering medical, scientific, regulatory, bioinformatic and
technical specialties. Its mission is to provide in-house sup-
port to clinical research, with a primary focus on clinical
monitoring, clinical trials, regulatory affairs, pre-analytics,
information technology (IT) and bioinformatics. It is fur-
ther responsible for collecting general consent forms
signed by CHUV patients, providing assistance in the re-
cruitment of clinical trial and research study participants,
informing about clinical research activities conducted with-
in the Institution, supervising the collection, storage and
management of biological samples for the BIL, providing
support to other institutional biobanks, and providing local
researchers with secured access to coded medical data and
information.
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Familial hypercholesterolaemia as a model disease
Familial hypercholsterolaemia (FH) was selected as a gen-
eric model of genetic disease that matched our needs for
a proof-of-concept study. FH is relatively common, auto-
somal dominant and of limited genetic complexity [2].
Depending on ethnicity, its frequency ranges from 1:500
to 1:200 heterozygous and around 1:1000000 homozygous
affected carriers in the general population [3, 4]. In most
cases, a single pathogenic variant is involved, primarily af-
fecting one of three genes: LDLR (60–80% of the cases),
APOB (1–5%), and PCSK9 (up to 3%). De novo mutations
and mutations in other genes have been described, yet re-
main rare. Oligogenic or polygenic forms have been ob-
served too. Although the number of implicated genes is
limited, the diversity of the underlying variants is broad,
with over 1500 variants documented for LDLR [5]. Disease
penetrance is high (90–100%), but expressivity varies de-
pending on the nature of the mutation [6].
The clinical significance of FH is well established. Male
carriers are at ≈50% risk of experiencing a major cardi-
ovascular insult before the age of 55 and females at ≈30%
before that of 60 [3]. These percentages are up to twenty-
fold higher than in subjects not carrying a mutation and add
on to classical risk factors for cardiovascular disease, typic-
ally obesity, hypertension, diabetes, smoking and sedentar-
iness [3, 7]. FH is clinically actionable: well-tolerated stat-
ins and other lipid-lowering compounds allow for first-line
preventive and therapeutic management, altogether con-
tributing to an up to two-fold reduction in cardiovascular
risk [8, 9]. However, although effective, these regimens
are often insufficient to achieve recommended low-density
lipoprotein cholesterol (LDL-C) goals in affected subjects.
Owing to their marked potency at further reducing plasma
LDL-C in patients receiving maximally tolerated statin
therapy, proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors recently emerged as a promising novel
class of biological agents capable of minimising residual
cardiovascular risk [9–12].
Whereas genetic testing is essential to confirm the clinical
diagnosis of FH, it is neither routinely performed nor reim-
bursed by the Swiss healthcare system. In the absence of
any dedicated screening programme, the percentage of un-
diagnosed FH carriers likely exceeds 80% in this country
[8]. In practice, diagnosis essentially rests on the calcu-
lation of clinical risk scores pertaining to criteria of per-
sonal or familial history of premature cardiovascular dis-
ease, elevated levels of blood cholesterol – in particular
LDL-C – and lipid (cholesterol) deposits around tendons
[6, 8]. Assessing those scores in a multicentre, Switzerland-
based cohort of 4478 participants, Nanchen et al. recently
estimated that up to 50% of those hospitalised for prema-
ture acute coronary syndrome (ACS), defined as ACS af-
fecting males before the age of 55 and females before the
age of 60, presented with a possible, probable or defin-
ite risk for FH [13]. While those results still need genetic
confirmation, unpublished analyses of longitudinal CoLaus
[14] data further indicate that >60% of adults with a clinical
diagnosis of possible FH are inappropriately treated over 5
years of follow-up (Nanchen et al. personal communication
2015). Taken together, these observations highlight the pat-
ent need for improved clinical management and guidelines
for FH in Switzerland.
LDLR or APOB mutations are detected in approximately
60% of patients with a definite risk for FH and in 20 to
30% of those with a possible risk [15]. Accordingly, the
likelihood of carrying pathogenic mutations in FH genes
strongly correlates with LDL-C levels. Circulating concen-
trations of total and LDL cholesterol in heterozygous FH
patients typically range from 9–14 mM and 5–10 mM, re-
spectively, reaching up to 17–26 mM and >15.5 mM in ho-
mozygous patients [6]. Interestingly, using extreme values
of total cholesterol as sole stratification criterion for genet-
ic testing is sufficient to enrich for LDLR mutation carri-
er detection [16]. Since blood values of (mainly total) cho-
lesterol are routinely monitored at the CHUV, we reasoned
that the number of BIL participants with documented cho-
lesterol measurements would be high, and that these data
would be easily retrievable from the corresponding hospital
records.
For the reasons listed above, FH was an optimal model to
test the procedures and support provided by the PSRC.
Materials and methods
Clinical and laboratory data extraction
All data and biological samples relate to BIL participants
who signed the general consent for clinical research (for
additional details, see [1]). Data extraction and crossing
through clinical and/or personal information were per-
formed by authorised personnel of the Institution, follow-
ing secured procedures validated by the Institution. The
following categories of information were extracted and the
results were provided to the researchers in the form of in-
dependent lists of coded or anonymised data, depending on
the nature of each item:
‒ general information: date of birth, gender, body weight,
height, date(s) of hospital stay(s);
‒ laboratory values spanning years 2004 to 2014, each
with the corresponding date of measurement: LDL-C
and TC for 5111 participants; triglycerides (TG), creat-
inine, glycaemia, thyroid stimulating hormone (TSH),
triiodothyronine (T3) and thyroxine (T4) for the set of
94 selected patients;
‒ prescriptions of statin(s) and/or other lipid-lowering
therapies at time of hospitalisation and/or during hos-
pital stay: name, type, dose, date of prescription;
‒ International Classification of Diseases (ICD10) dia-
gnostic codes for any of the following: CAD or ACS,
diabetes, stroke, peripheral arterial disease, acquired
immunodeficiency syndrome (AIDS), nephrotic syn-
drome, renal failure, dialysis, alcohol dependence, hy-
perglycaemia, hypothyroidism.
Patients positive for human immunodeficiency virus
(HIV), nephrotic syndrome, renal failure or a prescription
for dialysis, or for whom the quality of genomic DNA did
not comply with high throughput DNA sequencing require-
ments were excluded from further analyses.
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Purification of genomic DNA
Genomic DNA was extracted by LGC Genomics, Hoddes-
don (UK), starting from frozen buffy coat collected from
EDTA-blood samples. Procedures complied with good
laboratory practice (GLP). DNA quantities and qualities
were verified at the Genomic Technologies Facility (GTF)
of UNIL, using the Nanodrop (Thermo Scientific) and
Fragment Analyzer (Advanced Analytical) systems.
High-throughput DNA sequencing
The ADH MASTR v2 kit (Multiplicom), an amplicon-
based gene panel targeting all exons, 5’UTRs and 300
to 500 base-pair promoter regions of LDLR, PCSK9 and
APOE, together with exon 26 of APOB was used for high
throughput DNA sequencing (supplementary table 2). An
additional 12 common single nucleotide polymorphisms
(SNPs) are included in the assay, allowing for polygenic
risk score calculation for FH [34]. Library preparation and
250 nucleotide paired-end sequencing on the Illumina
MiSeq system were performed at the GTF, closely follow-
ing the recommendations of the supplier. Ten samples were
tested in a pilot phase and 84 were multiplexed in a second,
larger assay.
Approximately 2×20 mio sequencing reads were produced
in each run. Illumina software was used for base-calling
and demultiplexing on the MiSeq instrument. Given its link
with Alzheimer’s disease, APOE was masked from down-
stream analyses, while in absence of control patients, poly-
genic risk scores were not assessed.
The variant calling workflow consisted of a set of standard
open source tools [35]. The main steps were: (1) trimming
of low-quality bases and sequencing adapters at read ends
using FastqMcf; (2) sequencing read mapping onto the hu-
man reference genome (hg19) using BWA-MEM [36]; (3)
local realignment around small insertions/deletions using
GATK; (4) base quality score recalibration using GATK;
(5) removal of polymerase chain reaction (PCR) primers
using a custom Perl script; (6) variant calling using the
GATK unified genotyper tool; and (7) removal of low-
quality variants. At the end of the process, variant call
format (VCF) files were imported into Annovar (wanno-
var.usc.edu) to annotate variants. The most relevant an-
notations for variant assessment include those of ClinVar
(www.ncbi.nlm.nih.gov/clinvar), OMIM
(www.omim.org/), LOVD (www.lovd.nl), HGMD public
(www.hgmd.cf.ac.uk), ExAC (exac.broadinstitute.org),
dbSNP (www.ncbi.nlm.nih.gov/SNP), 1000 genomes
(www.1000genomes.org) and EVS
(evs.gs.washington.edu) databases and servers. The full list
of annotation databases is available at annov-
ar.openbioinformatics.org/en/latest/user-guide/download/.
Confirmatory Sanger sequencing
Genomic fragments covering LDLR and APOB variants
were amplified by touch-down PCR using specific primers
(Microsynth). For APOB p.R3527Q: 5’-
GAGTCATCTACCAAAGGAGATG-3’ and 5’-
TGCTCCCAGAG-GGAATATATGC-3’; for LDLR
p.C27W: 5’-GACTGTTCCTGATCGGATGAC-3’ and 5’-
TCTCCTGGGACTCATCAGAGC-3’; for LDLR
p.P526S: 5’-CAGAGGCTGAGGCTGCAGTGG-3’ and
5’-GTGAGACATTGTCACTATCTCC-3’; and for LDLR
p.V736I: 5’-CTGTGGACTGGATCCACAGC-3’ and 5’-
CACTAACCAGTTCCTGAAGC-3’. PCR conditions con-
sisted of 3 min denaturation at 94°C, 46 cycles of 1 min de-
naturation at 94°C, 1 min annealing at progressively lower
temperatures (i.e. starting from 1 cycle at 68°C, followed
by 2 cycles at 66°C, 3 cycles at 64°C, 4 cycles at 62°C, 5
cycles at 60°C, 6 cycles at 58°C and 25 cycles at 56°C),
and 1 min elongation at 72°C, followed by a final extension
of 10 min at 72°C. Bi-directional sequencing of the PCR-
amplified genomic fragments was performed on an ABI
3500 sequencer (PE Biosystems) using standard methods.
Sample identity coding
Data storage management and confidentiality were
provided by the PSRC information technology unit in close
collaboration with the CHUV information systems depart-
ment. In agreement with US Food and Drug Administration
(FDA) [37], European Union (EU) [38] and Organization
for Economic Collaboration and Development (OECD)
[39] recommendations for privacy and security of genomic
data, a double encoding procedure was used, where a coded
identifier, different from the permanent patient identifier of
the hospital, was assigned to each BIL participant, unique
2D-barcodes were assigned to each biological sample, and
distinct unique identifiers were used for genetic data.
Ethics
The protocol of the present study was submitted to the Re-
search Ethics Committee of the Canton of Vaud (CER-VD,
Lausanne, Switzerland) in June 2015 and granted author-
isation on 21 August 2015. Protocol number: 273/15.
Figure 1
Selection scheme of 94 BIL participants for FH genetic testing and
analysis workflow.
*As of April 26, 2015.
BIL = Lausanne Institutional Biobank; CAD = coronary artery
disease; LDL-C = low-density lipoprotein cholesterol; PSRC = an
integrated in-house clinical research support platform; TC = total
cholesterol
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Results
Data extraction
At time of data extraction (26 April 2015), 23 737 CHUV
patients had been contacted by the BIL and PSRC. Of the
17 760 (74.8%) consenting participants, 13 094 (73.7%)
wished to be recontacted if there were findings requiring
Figure 2
Mean amplicon coverage. Each bar corresponds to one of the 84
samples tested in the second sequencing run. Samples are ranked
from the lowest to the highest fold-coverage value. Fold-coverage
values of the first 10 samples ranged from 44 978 to 53 336 (data
not shown).
Figure 3
Number of variants identified in each of the 94 patients for APOB,
LDLR, and PCSK9. Each bar corresponds to a single sample.
Figure 4
Number of SNVs and indels identified in each of the 94 patients for
APOB, LDLR, and PCSK9. Each bar corresponds to a single
sample.
SNV = single nucleotide variant; indel = short insertion and/or
deletion
clinical action. For 5111 of the latter, a minimum of one
plasma total cholesterol (TC) value could be extracted from
electronic hospital records, spanning the years 2004 to
2014 (fig. 1). Among the 5111 patients, 2291 had also been
tested at least once for LDL-C.
Selection of a priority set of 94 patients
Given the 1:500 to 1:200 prevalence of FH in Switzerland,
a sample of 5111 unselected patients was expected to in-
clude 10 to 25 FH mutation carriers. To enrich for those in-
dividuals in our selection procedure, we relied on criteria of
elevated TC and/or LDL-C as well as young age (18–55 yr
in males, 18–60 yr in females) and presence of premature
coronary artery disease (CAD) at the time of cholesterol
testing. Our initial intention was to select subjects present-
ing at least once with TC >8.5 mM, a cut-off suggested
as clinically useful for the detection of FH by genetic test-
ing [16]. Since only 41 such patients were retrieved, while
up to 94 samples could be sequenced in parallel, we re-
laxed our inclusion criteria, ultimately prioritising subjects
presenting either with (1) early CAD, and TC ≥7.5 mM or
LDL-C ≥5 mM at least once, or (2) no CAD, but TC >7.7
mM or LDL-C ≥5 mM at least once, irrespective of treat-
ment (fig. 1). A concentration of LDL-C ≥5 mM matches
the minimum criterion for possible FH, as defined by the
Dutch Lipid Clinic network [6]. Here, all patients present-
ing with at least one such value were selected. While treat-
ment status was not considered for selection, retrospective
inspection indicated that all subjects with at least one value
of plasma LDL-C ≥4 mM when under statin(s) or lipid-
lowering therapy were included.
Genetic testing
Genetic testing was performed by high throughput DNA
sequencing of LDLR, APOB, and PCSK9 (see Methods).
Resulting mean amplicon coverage was far above the usual
requirements for germline sequencing, exceeding
4000-fold in almost all samples (fig. 2). Moreover, cover-
age uniformity was close to complete, with 100% of the
targeted bases covered 30-fold or higher in 87 samples and
>99.9% in the others. Overall, these results demonstrate ex-
cellent sequencing quality.
On average, 25 ± 3 (mean ± standard deviation) variants
were detected in each patient (minimum 17, maximum 34;
fig. 3). The vast majority were single nucleotide variants
(SNVs) and the number of short insertions or deletions (in-
dels) did not exceed three in any sample (fig. 4). Of the
84 distinct variants identified in total, 43 affected LDLR,
5 APOB and 36 PCSK9 (see appendix, supplementary
table 1). According to the ExAC browser (ht-
tp://exac.broadinstitute.org, version of July 2015), 23
SNVs were rare [i.e. occurring at global minor allele fre-
quencies (MAF) <1% in the general population], while
the others were common polymorphisms. Among the rare
SNVs, eight coded for missense amino acids and five for
synonymous variants, one was in a 3’UTR and nine were
intronic (table 1).
None of the intronic variants was predicted to affect mes-
senger RNA (mRNA) splicing (data not shown). Therefore,
to identify likely causative mutations for FH, we restricted
our investigations to low-frequency (MAF <1% in ExAC)
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missense coding variants. All of these heterozygous vari-
ants were documented in ExAC, indicating that none was
novel.
We excluded two known SNVs from the list of candidates
because of lack of evidence for a causal link with FH
in the literature and/or databases relevant to FH (namely
ClinVar [17], UCL [18], LOVD [5] and HGMD public
[19]). The first one, PCSK9 p.A443T (rs28362263; gen-
omic coordinates: chr1:55523855 G>A), is associated with
reduced plasma LDL-C [20]. The second one, APOB
p.Q3432E (rs1042023; genomic coordinates:
chr2:21229446 G>C), was detected in four carriers and
considered of low interest because of a lack of cosegreg-
ation with hypercholesterolaemia [21–24] and a classifica-
tion as “likely benign for FH” in ClinVar.
Assessments of the remaining six missense coding variants
were based on allele frequencies, predicted and/or experi-
mentally demonstrated functional impact (focusing on pre-
dictive CADD scores of nonfunctionality [25] and on an
extensive functional study of LDLR mutations [26]), and
clinical relevance. Three variants were considered as
pathogenic (APOB p.R3527Q) or likely pathogenic (LDLR
p.C27W and LDLR p.P526S) for hypercholesterolaemia,
whereas the others were of either uncertain or unknown
significance (table 2). The most significant variants were
verified by Sanger sequencing (fig. 5). Although the num-
ber of pathogenic mutation carriers was small, thus pre-
venting further statistical demonstration, we note that LDL-
C and TC plasma levels of patients 65 and 82 were among
the highest values documented for the set of 94 high-cho-
lesterol subjects, a trend expected to FH (fig. 6). In con-
trast, mean cholesterol levels of patients 39, 50 and 73, who
carried potentially less damaging variants, were lower than
the clinically relevant thresholds of 4.9 mM for LDL-C and
7.5 mM for TC.
Discussion
The major finding of this work consists of the identification
of seven carriers of rare, missense heterozygous coding
variants in FH genes among 94 high-cholesterol parti-
cipants in the BIL. Given the proof-of-concept nature of
our study, these results are remarkable as they were ob-
tained by applying a relatively crude analytical workflow,
where laboratory and clinical data extracted from electron-
ic hospital records of 5111 consenting participants were
used to enrich for mutation carriers within a small test set
of 94 selected individuals, and high-throughput DNA se-
Figure 5
Confirmatory Sanger sequencing. The most clinically relevant
variants of patients 82 (panels A, B), 65 (panel C) and 73 (panel D)
were confirmed by bidirectional Sanger sequencing. Each panel
shows chromatograms of the forward (top) and reverse (bottom)
sequencing reactions, together with the corresponding reference
sequences on the (+) and (–) strands (hg19). The variants are
boxed in grey on the chromatograms; the corresponding positions
on the reference sequence are highlighted in red; the stretch of
reference sequence shown in the respective chromatograms is in
bold letters. APOB is coded by the (-) strand, LDLR is coded by the
(+) strand.
Table 1: Types of genetic variants identified in the set of 94 selected patients.
APOB LDLR PCSK9 TOTAL
Variants, all 5 45 36 86
1. MAF(ExAC) ≤1% 3 12 8 23
- SNVs 3 12 8 23
- Coding 3 6 4 13
- Non-synonymous 2 5 1 8
- Nonsense 0 0 0 0
- Frameshift 0 0 0 0
- Upstream 0 0 0 0
- 3’UTR 0 0 1 1
- Intronic 0 6 3 9
- Indels 0 0 0 0
2. MAF(ExAC) = 1–2% 0 2 0 2
- Intronic 0 1 0 1
- ncRNA 0 1 0 1
MAF(ExAC): minor allele frequency as reported in the ExAC database; SNV = single nucleotide variant; UTR = untranslated region
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quencing allowed for targeted genetic screening of the ma-
jor FH genes.
Given the prevalence of FH, an estimated 10 to 20 carriers
of pathogenic mutations were expected. In reality, eight
rare LDLR and/or APOB missense variants were identified,
a number slightly below our predictions. Although presum-
ably not reaching top performance in terms of sensitiv-
ity, our results compare well with the approximately 2%
pathogenic mutation carriers identified by Norsworthy et
al. upon testing a population of 193 hypercholesterolaem-
ic primary care patients and applying selection criteria sim-
ilar to ours [27]. Moreover, Futema et al. clearly demon-
strated that using elevated cholesterol as the sole inclusion
criterion for genetic testing was particularly efficient when
considering extreme laboratory values (i.e. above 9 to 10
mM for TC), while specificity dropped quickly at lower
levels, typically reaching less than 5% when applying re-
laxed thresholds of 7.5 to 7.7 mM TC, as was done here
[16]. More recently, these observations were confirmed in
the large study of Khera et al. who identified <2% FH
mutation carriers in a cohort of 20 485 multiethnic parti-
cipants presenting plasma LDL-C >4.9 mM [7]. Interest-
ingly, this study also showed that, for a given LDL-C level
in plasma, carriers of FH-causing mutations were at a much
higher risk than noncarriers, providing strong support for
the concept of adding genetic information when predicting
CAD risk in suspected FH patients.
There are several explanations for suboptimal detection
sensitivity. For the sake of simplicity, patient stratification
and selection were performed regardless of treatment type
and status, and no correction for age, gender or treatment
was applied. Therefore, a number of mutation carriers may
have escaped prioritisation, in particular those for whom
cholesterol was monitored only in the presence of lipid-
lowering treatment, reaching nominal values below 7.5
mM for TC and 4 mM for LDL-C. To improve detection
efficiency, these data could be corrected for the type and in-
tensity of therapy used [7, 28], but such a task was beyond
our basic aims. A second limitation relates to the identific-
ation of (large) structural variants (SVs), which are not de-
tected by amplicon-based sequencing. Also, while prelim-
inary investigations did not point at copy number variants
(CNVs) in our dataset (data not shown), we lacked prop-
er positive controls to verify the reliability of those results.
Further, one should keep in mind that a few genes other
than LDLR, APOB, and PCSK9 are known to contribute to
rare forms of FH [29, 30], but were not tested. And last, a
few of the hypercholesterolaemic patients may be affected
by oligo- or polygenic forms of FH, which we did not in-
vestigate.
Three of the rare APOB and LDLR variants comply with
“pathogenic” or “likely pathogenic” clinical classifications
[31]. Essentially based on existing variant annotations and
published data, these assertions warrant further assessment
and clinical validation by a panel of expert reviewers. Tent-
ative scoring of the rare variant carriers using the data in
table 2 and the criteria of the Dutch Lipid Clinic network
[6] tend to suggest that patients 65 and 82, who carry the
Table 2: Details of the primary rare, missense, coding variants. Data are presented for five variant carriers, two females, three males. All of these patients were aged 18-60
yr at time of top cholesterol testing and presented with plasma triglyceride levels ≤2.2 mM.
Patient 39 Patient 50 Patient 65 Patient 73 Patient 82
Variant(s) LDLR p.R595Q LDLR p.G269D LDLR p.C27W LDLR p.V736I (1) APOB p.R3527Q
(2) LDLR p.P526S
Genomic coordinates 19:11227613 G>A 19:11217352 G>A 19:11210912 C>T 19:11233915 G>A (1) 2:21229160 C>T
(2) 19:11224428 C>T
dbSNP ID rs201102492 rs143992984 NA rs547268730 (1) rs5742904;
(2) NA
MAF (ExAC) 4.942×10–5 0.0002 1.65×10–5 2.475×10–5 (1) 0.0002
(2) 1.66×10-5
CADD score [25] 22.8 (high); see also [26] 11.28 (moderate) 16.97 (high) 6.505 (low) (1) 19.81 (high)
(2) 20.1 (high)
LOVD/HGMD annotation and
assertion
FH, probably pathogenic FH, Rome allele FH, San Francisco
allele
NA (1) ApoB deficiency;
cosegregates with ADH;
is the most frequent
mutation for FH/ADH
(2) FH, Cincinatti allele,
reduced LDLR activity
CLINVAR assertion Not asserted Uncertain significance for
FH
Not referenced Not referenced (1) Pathogenic, likely
pathogenic for FH (see
OMIM #107730 [40]; to
be reported (ACMG, [31])
(2) Not asserted
Functional testing and clinical
assertion by Thormaehlen et al.
[26]
Not disruptive; found in a
patient with MI and in an
unaffected control;
pathogenic for MI
Not disruptive (see also
[41]); found in a patient
with MI; pathogenic for MI
Not tested Not tested (1) NA
(2) Disruptive; found in a
patient with high LDL-C;
pathogenic for high LDL-
C
Confirmation by Sanger (fig. 5) NA NA YES YES (1) YES
(2) YES
Diagnostic No CAD No CAD Premature CAD Premature CAD Premature CAD
Statins/LLT No No Yes Yes Yes
ACMG: American college of medical genetics; HGMD: human gene mutation database; LLT: lipid-lowering therapy; NA: not applicable; LOVD: Leiden open (source)
variation database.
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most damaging mutations, suffered stronger clinical mani-
festations than subjects 39, 50 and 73 (data not shown).
In the absence of more comprehensive information, com-
plementary clinical investigations will be necessary to con-
firm risk scoring and diagnosis. Nonetheless, our results
provide important insights into information feedback to re-
search study participants, a process formally supported by
the general consent of the BIL [1]. Of note, the design of an
appropriate feedback procedure will be the task of a dedic-
A
B
Figure 6
Cholesterol levels measured in carriers vs non carriers of rare,
missense APOB and LDLR variants. Average LDL-C (panel A) and
TC (panel B) levels were computed for each of the high-cholesterol
patients tested by sequencing, irrespective of treatment. At least
one value of LDL-C was available for 65 of the 94 subjects [n = 2 ±
4 data points per patient (mean ± SD)], while TC was measured at
least once in all of them [n = 5 ± 6 data points per patient (mean ±
SD)]. Data are presented as means ± standard error of the mean
and are ranked from the lowest to the highest mean value. Data
points referring to the carriers of pathogenic (patient #82) or likely
pathogenic (patient #65) variants for FH are highlighted in red,
while those referring to carriers of rare variants of unknown
significance are highlighted in dark grey (patients #39, 73, and 50).
The clinical thresholds of high LDL-C (4.9 mM) and TC (7.5 mM)
are indicated by the green lines.
FH = familial hypercholesterolaemia; LDL-C = low-density
lipoprotein cholesterol; TC = total cholesterol
ated working group, whose conclusions and recommenda-
tions will be the topic of a separate report.
Linking data derived from electronic hospital records to
biological samples stored in biobanks such as the BIL en-
ables cost- and time-effective research. According to com-
parisons with more traditional approaches, the total time
and study cost necessary to recruit a cohort of a few hun-
dred participants, phenotype each subject, collect biologic-
al specimens and proceed to genotyping can be reduced by
up to 8- and 15-fold, respectively [32]. In a large biobank
like the BIL, storage of biological specimens is often re-
stricted to a small array of samples, typically DNA and
plasma. However, the principle of the general consent [1]
makes it possible to recontact consenting participants,
thereby enabling subsequent enrichment with additional
specimens and/or clinical data. These benefits may be amp-
lified further by pooling analyses across collaborative net-
works, leading to an increase in sample sizes and minim-
isation of biases [33]. Networks will be instrumental in in-
vestigating rare diseases and/or rare variants, screening for
specific variant carriers in larger pools of samples, cross-
ing or replicating results with information gained in inde-
pendent cohorts, or accessing complementary information
or samples from other repositories. As recognised earli-
er, strong support structures will be necessary to stream-
line efficient and effective communication and manage-
ment among the research teams and networks involved
[32].
At the local level, the present study illustrates the capab-
ilities of the PSRC and its partners to provide efficient
assistance and support to research centered on genomic
medicine, in particular for the recruitment of consenting
patients, the secured management of high-quality biologic-
al samples and medical data, and the generation and ana-
lysis of genetic profiles. To address similar needs, and also
to ascertain research quality and interconnectedness across
biobanks at the national level, the Swiss National Science
Foundation, the Swiss Academy of Medical Sciences
(SAMS) and a dedicated Project Group recently launched
the Swiss Biobanking Platform (SBP; ht-
tp://www.swissbiobanking.ch/). The mission of the SBP
will be to develop a reliable customer-oriented network
across Swiss biobanks, with harmonised processes for gen-
eral information and consent, pre-analytical sample pro-
cessing and storage, laboratory informatics management
systems, data storage and confidentiality, annotation of
samples and data, traceability, access and distribution of
samples and data to researchers, support to investigators
and biobank sustainability.
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Figures (large format)
Figure 1
Selection scheme of 94 BIL participants for FH genetic testing and analysis workflow.
*As of April 26, 2015.
BIL = Lausanne Institutional Biobank; CAD = coronary artery disease; LDL-C = low-density lipoprotein cholesterol; PSRC = an integrated in-
house clinical research support platform; TC = total cholesterol
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Figure 2
Mean amplicon coverage. Each bar corresponds to one of the 84 samples tested in the second sequencing run. Samples are ranked from the
lowest to the highest fold-coverage value. Fold-coverage values of the first 10 samples ranged from 44 978 to 53 336 (data not shown).
Figure 3
Number of variants identified in each of the 94 patients for APOB, LDLR, and PCSK9. Each bar corresponds to a single sample.
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Figure 4
Number of SNVs and indels identified in each of the 94 patients for APOB, LDLR, and PCSK9. Each bar corresponds to a single sample.
SNV = single nucleotide variant; indel = short insertion and/or deletion
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Figure 5
Confirmatory Sanger sequencing. The most clinically relevant variants of patients 82 (A, B), 65 (C) and 73 (D) were confirmed by bidirectional
Sanger sequencing. Each panel shows chromatograms of the forward (top) and reverse (bottom) sequencing reactions, together with the
corresponding reference sequences on the (+) and (–) strands (hg19). The variants are boxed in grey on the chromatograms; the corresponding
positions on the reference sequence are highlighted in red; the stretch of reference sequence shown in the respective chromatograms is in bold
letters. APOB is coded by the (-) strand, LDLR is coded by the (+) strand.
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Figure 6
Cholesterol levels measured in carriers vs non carriers of rare, missense APOB and LDLR variants. Average LDL-C (panel A) and TC (panel
B) levels were computed for each of the high-cholesterol patients tested by sequencing, irrespective of treatment. At least one value of LDL-C
was available for 65 of the 94 subjects [n = 2 ± 4 data points per patient (mean ± SD)], while TC was measured at least once in all of them [n = 5
± 6 data points per patient (mean ± SD)]. Data are presented as means ± standard error of the mean and are ranked from the lowest to the
highest mean value. Data points referring to the carriers of pathogenic (patient #82) or likely pathogenic (patient #65) variants for FH are
highlighted in red, while those referring to carriers of rare variants of unknown significance are highlighted in dark grey (patients #39, 73, and
50). The clinical thresholds of high LDL-C (4.9 mM) and TC (7.5 mM) are indicated by the green lines.
FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol
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